GlassScriptPhysician profile
Becky B Raby
NPI 1295712933
$2,232.53
in general payments reported to CMS, 2019-2025
16 companies · $592 in 2025
The $592 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $203 · 2023: $126 · 2024: $436 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $803.26 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $439.70 | 2023-2025 | Cuvitru |
| Csl Behring | $430.78 | 2019-2024 | Hizentra |
| Genzyme Corporation | $122.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $121.65 | 2019-2020 | |
| Genentech USA, INC. | $70.48 | 2019-2020 | |
| Ucb, INC. | $50.37 | 2019 | |
| Lilly USA, LLC | $35.40 | 2019 | |
| Sun Pharmaceutical Industries INC. | $31.89 | 2019 | |
| Glaxosmithkline, LLC. | $30.69 | 2019-2020 | |
| Optinose US, INC. | $26.64 | 2019-2020 | |
| Grifols USA, LLC | $19.78 | 2020 | |
| Amgen INC. | $13.52 | 2019 | |
| Almirall LLC | $12.50 | 2019 | |
| Dermira, INC. | $12.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Becky Raby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.